Xarelto Lawsuit Filed For Alleged Omission Of Data

March 23, 2016 – – BloodThinnerHelp.com reports on recent charges filed against Xarelto makers Johnson & Johnson and Bayer AG for allegedly leaving out data that may have been important in determining the blood-thinning drug’s safety.

Data about Xarelto was published in the New England Journal of Medicine by Duke researchers and is now the main focus of a lawsuit because of an allegedly faulty blood-testing device that was used in the drug trial. The clinical trial, called “Rocket AF” included 14,000 patients over a 3-year period and was compared to the blood-thinning drug warfarin. Companies informed regulators that the blood-testing device had not been working properly during the research trial about five years after the drug had reached the market. As a result, researchers may have given patients the wrong dosage of warfarin, leading to the belief that Xarelto was more effective, the FDA said. Recently lawyers have argued that the companies knowingly ignored Duke’s omission of data regarding a blood-testing device. As a result, they allege that these companies contributed to misleading the NEJM. Both companies assert that they sent all the required data to regulators in Europe and the U.S.

Xarelto was first introduced to the United States in 2011. According to several studies, and adverse events reported by the FDA, Xarelto has been suggested as the primary cause for internal bleeding and gastrointestinal bleeds. The first lawsuit filed alleging Xarelto was the cause of a patient’s death because of uncontrollable bleeding occurred in January 2014. Other common adverse side effects that patients have associated with the drug include brain hemorrhages, rectal bleeding, pulmonary embolisms (blood clots in the lung), epidural hematoma, stroke, and heart attacks. At the time of the drug’s release to the market there was no known reversal agent for Xarelto.

Many believe that Xarelto lawsuits will continue to be filed as trial dates approach. Attorney Joseph Osborne is currently working to assist patients who used Xarelto and believe they have suffered adverse side effects from the drug. Those individuals may be entitled to legal action and compensation. Osborne greatly encourages those affected to investigate their legal opportunities fully. Osborne is offering complimentary legal consultations at this time.

For more information or questions on Xarelto, please contact Joseph Osborne, Esq., by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008824